Abstract
In this article, a new look at cardiac rhythm and conduction disorders in children is outlined. These deviations, along with congenital malformations, have taken one of the first places in the structure of cardiovascular pathologies. This is one of the most serious problems that stands at the intersection of cardiology and pediatrics. The frequency of occurrence of severe forms of arrhythmias reaches 1:5000 of the child population, and life-threatening arrhythmias – 1:7000. Treatment of cardiac arrhythmias and conduction disorders is one of the most difficult sections of clinical pediatrics. There are medicinal and non-medicinal methods. According to experimental new data, nootropics, in particular the drug Cortexin, along with cardiotrophic drugs, form the basis of neuro-metabolic therapy and correction of children's arrhythmias.
Highlights
Cardiac rhythm and conduction disorders, along with congenital heart defects, have taken one of the first places in the structure of cardiovascular pathology in children [1,2,3]
According to Holter monitoring data, from 50 to 90% of conditionally healthy children have some kind of heart rhythm disorders [5]
These pathologies are most often based on organic heart lesions of congenital and acquired genesis [7]. Their cause may be myocardiodystrophy and myocardiofibrosis, developing with prolonged infectious and toxic myocardial damage. These pathologies occur in diseases of the endocrine system, the genesis of which is associated with both hormonal imbalance and secondary myocardial dystrophy [3,7]
Summary
Cardiac rhythm and conduction disorders, along with congenital heart defects, have taken one of the first places in the structure of cardiovascular pathology in children [1,2,3]. They occupy a leading place in the structure of pediatric cardiological morbidity and causes of mortality from cardiac arrhythmias (60-70%) [2,5] These pathologies are most often based on organic heart lesions of congenital and acquired genesis [7]. Their cause may be myocardiodystrophy and myocardiofibrosis, developing with prolonged infectious and toxic myocardial damage. The peptide complex of the drug Cortexin activates intracellular processes of regulation and antioxidant protection [14,15,16]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
